NKGen Biotech Presents Phase 1/2a Data On Troculeucel In Alzheimer's Disease At CTAD Conference, Showing Biomarker Reductions And Cognitive Improvement; Highest Dose Demonstrates Safety With Potential To Delay Dementia

Benzinga10/29 20:07

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga10/05 04:31

Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Benzinga09/17 17:48

NKGen Biotech Shares Are Trading Higher After the Company Announced Early Interim Data From the Phase 1 Cohort and the Dosing of the First Phase 2 Patient in the Phase 1/2a Clinical Trial of Troculeucel.

Benzinga09/12 20:13

NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Yahoo Finance09/03 20:05

NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report

Globe Newswire08/23 04:40